(Adds details throughout) Oct 3 (Reuters) – Rocket Pharmaceuticals said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder. The therapy RP-L102 was being tested in patients with Fanconi anemia, characterized by impaired bone marrow function which leads to a decrease in the production of blood cells. The company said the move was driven by business strategy and not by concerns about the treatment safety or efficacy. Rocket said it will consider external partnership opportunities for RP-L102. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
